| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Objective: The purpose of this project is to develop the assay for identifying the antigen against IgG from the patients with neuro-inflammatory disorders, which cause the BBB disruption using our human in vitro BBB model. Methods: We identified IgG from patients with the neuro-inflammatory disease, which induced NF-κB p65 nuclear translocation in human brain microendothelial cell lines (TY10). We developed the novel assay to detect cell-surface antigen against IgG from the neuro-inflammatory disease. Results: IgGs from paraneoplastic cerebellar degeneration (PCD) with Lambert-Eaton myasthenic syndrome (LEMS) [LEMS-PCD] shows the most ability to give rise to nuclear translocation of NF-κB p65. We detected glucose-regulated protein (GRP)78 autoantibodies in the IgG of LEMS-PCD. Conclusions: We identified GRP78 autoantibodies from LEMS-PCD patients having biological effects on BBB-endothelial cells.
|
